External Selective Laser Trabeculoplasty – Eagle Device

The Eagle device, developed by Belkin Vision, represents a significant advancement in the field of selective laser trabeculoplasty (SLT) for glaucoma treatment. Here are some key features and innovations associated with this device:

1. **Direct SLT Technique**: The Eagle employs a unique technique called "direct SLT" (DSLT). Unlike traditional SLT lasers that send pulses to the trabecular meshwork via a gonio lens, the Eagle's DSLT method allows laser energy to be applied directly through the peripheral cornea and the limbus. This approach eliminates the need for gonioscopy, a diagnostic procedure that requires a special contact lens to examine the front part of the eye.

2. **First of Its Kind**: The Eagle is recognized as the first DSLT laser. This distinction is notable because it changes the conventional approach to SLT, offering a more streamlined and potentially less invasive method.

3. FDA Clearance and Technical Specifications: Belkin Vision's Eagle device has received FDA 510(k) clearance, highlighting its compliance with safety and effectiveness standards required in the United States. Technically, the Eagle is a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser. It's specifically developed for performing SLT in glaucoma patients

4. **Contactless and Automated Laser for Glaucoma**: The Eagle is positioned as the first and only contactless laser for glaucoma. This feature represents a significant shift towards an automated and noninvasive solution for both patients and healthcare professionals. The contactless nature of the device could potentially reduce the risk of complications associated with contact procedures and streamline the treatment process

In summary, the Eagle by Belkin Vision introduces a novel approach to SLT, offering advantages such as a contactless, direct application of laser energy and an automated procedure. This innovative technology has the potential to enhance the efficiency and safety of glaucoma treatment.